Mutant KRAS Drives Immune Evasion by Sensitizing Cytotoxic T‐Cells to Activation‐Induced Cell Death in Colorectal Cancer
Abstract The roles of oncogenic KRAS in tumor immune evasion remain poorly understood. Here, mutant KRAS is identified as a key driver of tumor immune evasion in colorectal cancer (CRC). In human CRC specimens, a significant reduction in cytotoxic CD8+ T‐cell tumor infiltration is found in patients...
Main Authors: | Huashan Liu, Zhenxing Liang, Sijing Cheng, Liang Huang, Wenxin Li, Chi Zhou, Xiaobin Zheng, Shujuan Li, Ziwei Zeng, Liang Kang |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-02-01
|
Series: | Advanced Science |
Subjects: | |
Online Access: | https://doi.org/10.1002/advs.202203757 |
Similar Items
-
Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population
by: Lixiu Peng, et al.
Published: (2023-01-01) -
Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer
by: Hang Ruan, et al.
Published: (2022-03-01) -
Profiling oncogenic KRAS mutant drugs with a cell-based Lumit p-ERK immunoassay
by: Matthew Swiatnicki, et al.
Published: (2022-06-01) -
KRAS mutant lung cancer: progress thus far on an elusive therapeutic target
by: Saveri Bhattacharya, et al.
Published: (2015-12-01) -
Mutant KRAS-Associated Proteome Is Mainly Controlled by Exogenous Factors
by: Patrícia Dias Carvalho, et al.
Published: (2022-06-01)